1.91

2.14% 0.04

Inhibikase Therapeutics Inc (IKT)

Overview News Price History Financials Discussions Forecast Stock Split

Inhibikase Therapeutics Inc stock is traded at $1.91, with a volume of 3.82M. It is up +2.14% in the last 24 hours and up +12.35% over the past month. Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Previous Close:

$1.87

Open:

$1.835

24h Volume:

3.82M

Relative Volume:

4.13

Market Cap:

$252.18M

Revenue:

$79,600

Net Income/Loss:

$-48.26M

P/E Ratio:

-3.8805

EPS:

-0.4922

Net Cash Flow:

$-28.24M

1W Performance:

+4.37%

1M Performance:

+12.35%

6M Performance:

-4.50%

1Y Performance:

+15.76%

1-Day Range:

$1.835

$1.93

1-Week Range:

$1.785

$1.93

52-Week Range:

$1.33

$2.26

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name

Inhibikase Therapeutics Inc

Sector

Healthcare (1095)

Industry

Biotechnology (615)

Phone

(302) 295-3800

Address

1000 N. WEST STREET, SUITE 1200, WILMINGTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IKT Inhibikase Therapeutics Inc	1.91	252.18M	79,600	-48.26M	-28.24M	-0.4922
VRTX Vertex Pharmaceuticals Inc	491.34	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.90	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	887.18	55.17B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.37	38.90B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	182.08	38.71B	742.00K	-1.37B	-1.07B	-7.0731

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-04-26	Initiated	Ladenburg Thalmann	Buy
Jan-21-26	Initiated	BofA Securities	Buy
Dec-26-25	Initiated	H.C. Wainwright	Buy
Dec-11-25	Initiated	Cantor Fitzgerald	Overweight
Feb-12-25	Downgrade	H.C. Wainwright	Buy → Neutral

Inhibikase Therapeutics Inc Stock (IKT) Latest News

06:05 AM

Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections - Stock Titan

06:05 AM

01:19 AM

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com

01:19 AM

Jun 28, 2026

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026

Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView

Jun 28, 2026

Jun 27, 2026

Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView

Jun 27, 2026

Price to sales forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView

Jun 27, 2026

Price to sales forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView

Jun 27, 2026

Price to earnings forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView

Jun 27, 2026

Price to book forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView

Jun 27, 2026

Jun 26, 2026